Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients

International Journal of Dermatology

Volumn 52, Issue 3, 2013, Pages 358-362

  Vitiello, Magalys ^a   Tosti, Antonella ^b   Abuchar, Adriana ^a   Zaiac, Martin ^b   Kerdel, Francisco A ^a,b  

^a UNIVERSITY OF MIAMI HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE; PLACEBO; USTEKINUMAB;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MONOTHERAPY; NAIL PSORIASIS; NAIL PSORIASIS SEVERITY INDEX; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PSORIASIS; PSORIATIC ARTHRITIS; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873975682     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05320.x     Document Type: Article

References (11)

1. Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg 2009; 13: 102-106.
2. Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-271.
3. Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123-129.
4. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640.
5. Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69: 394-399.
6. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24: 530-534.
7. Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904.
8. Korver JEM, Langewouters AMG, Van De Kerkhof PCM, Pash MC. Therapeutic effects of a 12 week course of Alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252-1255.
9. Rich P, Griffiths CEM, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1year. J Am Acad Dermatol 2008; 58: 224-231.
10. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
11. Noiles K, Vender R. Nail psoriasis and biologics. Review. J Cutan Med Surg 2009; 13: 1-5.